Boditech Med Inc. (206640.KQ)

KRW 16600.0

(0.36%)

Total Liabilities Summary of Boditech Med Inc.

Boditech Med Inc.'s latest annual total liabilities in 2023 was 30.48 Billion KRW , up 46.39% from previous year.
Boditech Med Inc.'s latest quarterly total liabilities in 2024 Q2 was 29.99 Billion KRW , down -2.58% from previous quarter.
Boditech Med Inc. reported annual total liabilities of 20.82 Billion KRW in 2022, down -32.84% from previous year.
Boditech Med Inc. reported annual total liabilities of 31 Billion KRW in 2021, down -17.03% from previous year.
Boditech Med Inc. reported quarterly total liabilities of 29.99 Billion KRW for 2024 Q2, down -2.58% from previous quarter.
Boditech Med Inc. reported quarterly total liabilities of 21.68 Billion KRW for 2023 Q2, down -16.45% from previous quarter.

Annual Total Liabilities Chart of Boditech Med Inc. (2023 - 2015)

Historical Annual Total Liabilities of Boditech Med Inc. (2023 - 2015)

Year	Total Liabilities	Total Liabilities Growth
2023	30.48 Billion KRW	46.39%
2022	20.82 Billion KRW	-32.84%
2021	31 Billion KRW	-17.03%
2020	37.37 Billion KRW	54.73%
2019	24.15 Billion KRW	-31.8%
2018	35.41 Billion KRW	-16.35%
2017	42.33 Billion KRW	218.29%
2016	13.3 Billion KRW	-32.67%
2015	19.75 Billion KRW	0.0%

Year	Total Liabilities	Total Liabilities Growth
2024 Q1	30.78 Billion KRW	0.99%
2024 Q2	29.99 Billion KRW	-2.58%
2023 Q2	21.68 Billion KRW	-16.45%
2023 Q4	30.48 Billion KRW	21.62%
2023 FY	30.48 Billion KRW	46.39%
2023 Q3	25.06 Billion KRW	15.61%
2023 Q1	25.95 Billion KRW	24.61%
2022 Q1	30.26 Billion KRW	-2.4%
2022 Q3	23.1 Billion KRW	7.15%
2022 Q2	21.56 Billion KRW	-28.76%
2022 Q4	20.82 Billion KRW	-9.86%
2022 FY	20.82 Billion KRW	-32.84%
2021 FY	31 Billion KRW	-17.03%
2021 Q1	35.47 Billion KRW	-5.07%
2021 Q2	28.43 Billion KRW	-19.85%
2021 Q3	36.06 Billion KRW	26.84%
2021 Q4	31 Billion KRW	-14.03%
2020 Q2	26.59 Billion KRW	-0.11%
2020 Q4	37.37 Billion KRW	23.14%
2020 Q3	30.35 Billion KRW	14.12%
2020 Q1	26.62 Billion KRW	10.22%
2020 FY	37.37 Billion KRW	54.73%
2019 Q2	32.32 Billion KRW	-9.99%
2019 FY	24.15 Billion KRW	-31.8%
2019 Q4	24.15 Billion KRW	-1.44%
2019 Q3	24.5 Billion KRW	-24.19%
2019 Q1	35.91 Billion KRW	1.4%
2018 Q2	38.8 Billion KRW	-3.55%
2018 FY	35.41 Billion KRW	-16.35%
2018 Q4	35.41 Billion KRW	-2.59%
2018 Q1	40.23 Billion KRW	6.36%
2018 Q3	36.35 Billion KRW	-6.3%
2017 FY	42.33 Billion KRW	218.29%
2017 Q1	19.36 Billion KRW	65.67%
2017 Q2	36.11 Billion KRW	86.49%
2017 Q3	36.02 Billion KRW	-0.25%
2017 Q4	37.82 Billion KRW	5.0%
2016 Q3	16.57 Billion KRW	-3.25%
2016 Q1	16.79 Billion KRW	37.68%
2016 Q2	17.12 Billion KRW	1.96%
2016 FY	13.3 Billion KRW	-32.67%
2016 Q4	11.69 Billion KRW	-29.45%
2015 Q3	13.01 Billion KRW	0.0%
2015 FY	19.75 Billion KRW	0.0%
2015 Q4	12.2 Billion KRW	-6.22%

Peer Total Liabilities Comparison of Boditech Med Inc.

Name	Total Liabilities	Total Liabilities Difference
HLB Pharmaceutical Co., Ltd	53.19 Billion KRW	42.695%
CMG Pharmaceutical Co., Ltd.	40.02 Billion KRW	23.844%
Celltrion Pharm, Inc.	264.97 Billion KRW	88.495%
Huons Global Co., Ltd.	407.28 Billion KRW	92.515%
DongKook Pharmaceutical Co., Ltd.	263.36 Billion KRW	88.425%
Enzychem Lifesciences Corporation	16.91 Billion KRW	-80.184%
Humedix Co., Ltd.	21.91 Billion KRW	-39.108%
EuBiologics Co., Ltd.	67.82 Billion KRW	55.053%
FutureChem Co.,Ltd	8.91 Billion KRW	-241.807%
Huons Co., Ltd.	206.87 Billion KRW	85.264%
BNC Korea Co., Ltd.	21.94 Billion KRW	-38.91%
AptaBio Therapeutics Inc.	38.19 Billion KRW	20.179%